Background: Several studies indicate that immunohistochemical detection of the c-myc oncogene might serve as an additional prognostic marker in malignant melanoma. Objective: To study c-myc expression in paraffin-embedded cutaneous melanoma and to correlate to metastatic potential and onset of metastases. Methods: Cytoplasmic c-myc protein expression was visualized using the APAPP method, and reactivity (percent total tumor cells stained) was assessed in 62 formalin-fixed paraffin-embedded primary cutaneous melanomas (21 not metastasizing, mean Breslow 3.0 ± 2.9 mm, 41 metastasizing, mean Breslow 3.1 ± 3.0 mm) and 24 metastases of the same patients. Results: There was no significant difference of c-myc reactivity in cutaneous melanoma who did not metastasize (n = 21, c-myc reactivity 32.7 ± 19.3%, follow-up 10.6 ± 1.8 years) and primaries who metastasized (n = 41, c-myc reactivity 27.7 ± 22.4%, p = 0.29). This finding was independent of the thickness of the primary and was found within thin cutaneous melanoma with a Breslow <0.75 mm (range 0.24–0.65 mm, n = 20, c-myc reactivity 29.1 ± 15.7%, p = 0.32) or within thick cutaneous melanoma with a Breslow >1.5 mm (range 1.6–11 mm, n = 41, c-myc reactivity 29.6 ± 23.8%, p = 0.46). No correlation of c-myc expression between thin cutaneous melanoma, thick cutaneous melanoma (p = 0.83) or metastasizing primaries and their metastases (n = 24, c-myc reactivity 29.3 ± 22%) was found (p = 0.64). The time period until development of first metastasis did not correlate with the percentage of cells expressing c-myc in the primary (p = 0.56). Conclusion: c-myc expression is independent of metastatic potential and onset of metastases and, therefore, does not serve as a prognostic immunohistochemical marker in primary cutaneous melanoma.

1.
Breslow A: Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970;172: 902–908.
2.
Soong SJ, Shaw HM, Balch CM, McCarthy WH, Urist MM, Lee JY: Predicting survival and recurrence in localized melanoma: A multivariate approach. World J Surg 1992;16: 191–195.
3.
Böni R, Doguoglu A, Burg G, Müller B, Dummer R: MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma. J Am Acad Dermatol 1996;35:416–418.
4.
Lazaris AC, Theodoropoulos GE, Aroni K, Saetta A, Davaris PS: Immunohistochemical expression of c-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma. Virchows Arch 1995; 426:461–467.
5.
Mooy CM, Luzten GP, de Jong PT, Luider TM, Stijnen T, van de Ham F, van Vroonhoven CC, Bosman FT: Immunohistochemical and prognostic analysis of apoptosis and proliferation in uveal melanoma. Am J Pathol 1995;147: 1097–1104.
6.
Vogelstein B, Kinzler KW: The multistep nature of cancer. Trends Genet 1993;9:138–141.
7.
Alitalo K, Bishop JM, Smith DH, Chen EY, Colby WW, Levinson AD: Nucleotide sequence to the v-myc oncogene of avian retrovirus MC29. Proc Natl Acad Sci USA 1983;80: 100–104.
8.
Cole MD: Activation of the c-myc oncogene. Basic Life Sci 1986;38:399–406.
9.
Cole MD: Regulation and activation of c-myc. Nature 1985;318:510–511.
10.
Spencer CA, Groudine M: Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res 1991;56:1–48.
11.
Ahern TE, Bird RC, Bird AE, Wolfe LG: Overexpression of c-erb B-2 and c-myc but not c ras, in canine melanoma cell lines is associated with metastatic potential in nude mice. Anticancer Res 1993;13:1365–1371.
12.
Korabiowska M, Brinck U, Mirecka J, Kellner S, Marx D, Schauer A: Antigen Ki-67 and c myc oncogene as related to histoclinical parameters in pigmented skin lesions. In Vivo 1995;9:433–438.
13.
Blom DJ, Mooy CM, Luyten GP, Kerkvliet S, Ouwerkerk I, Zwinderman AH, Schrier PI, Jager MJ: Inverse correlation between expression of HLA-B and c-myc in uveal melanoma. J Pathol 1997;181:75–79.
14.
Grover R, Grobbelaar AO, Hudson DA, Forder M, Wilson GD, Sanders R: The clinical significance of oncogene expression in subungual melanoma. Br J Plast Surg 1997;50:15–19.
15.
Mason DY, Cordell JL, Abdulaziz Z, Naiem M, Bordenave G: Preparation of peroxidase:antiperoxidase (PAP) complexes for immunohistological labeling of monoclonal antibodies. J Histochem Cytochem 1982;30:1114–1122.
16.
Peltenburg LT, Steegenga WT, Kruse KM, Schrier PI: c-myc-induced natural killer cell sensitivity of human melanoma cells is reversed by HLA-B27 transfection. Eur J Immunol 1992;22:2737–2740.
17.
Griffioen M, Peltenburg LT, van Oorschot DA, Schrier PI: c-myc represses transiently transfected HLA class I promoter sequences not locus-specifically. Immunobiology 1995;193: 238–247.
18.
Alarcon RM, Rupnow BA, Graeber TG, Knox SJ, Giaccia AJ: Modulation of c-myc activity and apoptosis in vitro. Cancer Res 1996;56: 4315–4319.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.